Cantharimide Compounds with Bioactive Polymers for Selective Anti-Tumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cantharidin derivatives used as anti-tumor agents exhibit severe toxicity towards both cancer cells and normal cells, limiting their effectiveness in cancer treatment due to unclear molecular mechanisms of action and significant side effects.
Innovation Solution
Development of new cantharimide compounds with specific structural modifications, such as the backbone formula (1), which includes various functional groups and bioactive polymers, to enhance cytotoxicity towards cancer cells while reducing toxicity to normal cells, achieved through the condensation of 2-amino-benzothiazole compounds with cantharidin in a toluene-triethylamine mixture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cantharidin derivatives are used as anti-tumor agents, then cytotoxicity towards cancer cells is improved, but toxicity towards normal cells increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (carboxyl, hydroxyl, amino, ether, ester) at particular positions on the cantharimide core structure. These localized modifications create regions with different chemical properties that enable selective interaction with cancer cells versus normal cells, achieving differential toxicity through structural heterogeneity
Solution Approach 2:
The patent employs composite materials by combining the cantharimide scaffold with various heteroaryl groups (pyridine, pyrimidine, triazine rings) and diverse functional groups. This composite structural approach creates molecules with optimized properties that maintain anti-tumor activity while reducing normal cell toxicity through enhanced selectivity
2Reliability
If cantharidin derivatives are developed to enhance cytotoxicity, then anti-cancer effectiveness is improved, but side effects increase
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters including substituent types, positions, and configurations on the cantharimide structure. These parameter modifications tune the biological activity profile to achieve higher cytotoxicity towards cancer cells while minimizing side effects through optimized molecular properties
3Reliability
If traditional cantharidin is used for cancer treatment, then growth inhibition activity is achieved, but renal and gastrointestinal toxicity occurs
Solution Approach 1:
The patent applies the extraction principle by removing the toxic anhydride functional group from cantharidin and replacing it with a cantharimide structure. This extraction of the harmful component while retaining the growth inhibition activity through the modified cantharimide scaffold eliminates renal and gastrointestinal toxicity while preserving anti-tumor effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized cantharimide compounds demonstrate potent anti-tumor activity with reduced toxicity to normal cells, effectively inhibiting cancer cell proliferation and retarding tumor growth without significant adverse effects on vital organs, offering a potential improvement over traditional cantharidin derivatives in chemotherapy.
Implementation Method 1
a method of making a cantharimide compound may include preparing a 2-amino-benzothiazole compound and condensing the 2-amino-benzothiazole compound with a cantharidin in the presence of a toluene-triethylamine mixture
Data Source
AI summary
A cantharimide compound may include the backbone of formula (1). R1, R2, R3, and R4 may be independently selected from the group consisting of H, C(O)OR5, C(O)R6, C(O)NR7R8, NR9C(O)R10, N—R11R12, O—R13, S—R14, P(O)(OR15)(OR16), As(O)(OR17)(OR18), SO2R19, SO3R20, and B(OR21). X1 to X4 may be independently selected from the group consisting of nitrogen and carbon, such that X1 to X4 are not all hydrogen. Y1, Y2 and R5 to R21 may be independently selected from the group consisting of hydrogen, C1-12-alkyl, -aryl, heteroaryl, and a bioactive polymer.